Gene-Eden-VIR/Novirin Holds Promising Potential for Coronavirus Treatment

The coronavirus (COVID-19) outbreak has caused a significant threat to the global health, resulting in surging fatalities. Hence, companies in the human papillomavirus and cytomegalovirus therapeutics market are capitalizing on the ongoing coronavirus pandemic to increase its trials with Gene-Eden-VIR/Novirin that holds promising potentials for coronavirus treatment. Gene-Eden-VIR/Novirin is a patented herbal broad-spectrum antiviral treatment that has shown clinical evidence for HPV and cytomegalovirus treatment. Hence, companies in the human papillomavirus and cytomegalovirus therapeutics market are increasing awareness for Gene-Eden-VIR/Novirin.

Gene-Eden-VIR/Novirin is being currently tested for COVID-19, since coronavirus is closely related to the human Severe Acute Respiratory Syndrome (SARS-CoV), owing to its high sequence identity. Hence, companies in the market for human papillomavirus and cytomegalovirus therapeutics are increasing their trials in several existing drugs that are found effective against RNA viruses such as the coronavirus.

Request a sample to get extensive insights into the Human Papillomavirus and Cytomegalovirus Therapeutics Market 

Nanotechnology Improves Pharmacological Techniques in Human Papillomavirus and Cytomegalovirus Therapeutics Market

Human papillomavirus (HPV) is one of key drivers responsible for most cervical cancer cases worldwide. Hence, companies in the market for human papillomavirus and cytomegalovirus therapeutics are tapping opportunities in nanotechnology for the treatment of viral infection and cancer. Such efforts of companies are reflecting in revenue growth for human papillomavirus therapeutics. As such, DNA Nano-based drug carriers are being highly publicized, owing to its bioavailability and these drugs are gaining prominence in antiviral and anticancer drugs of the human papillomavirus and cytomegalovirus therapeutics market.

AS1411 is a G-quadruplex (G4)-forming DNA oligonucleotide that is found at high levels on the surface of cancer cells. Hence, companies in the market for human papillomavirus and cytomegalovirus therapeutics are increasing their efforts in clinical trials for AS1411, since the protein holds promising potentials pharmacology and cancer treatment.

Ganciclovir and Cidofovir Highly Preferred Treatments for Cytomegalovirus

Ganciclovir is considered as the gold standard for active cytomegalovirus treatment. As such, Ganciclovir/Valganciclovir is estimated to dictate the highest revenue among all drugs in the cytomegalovirus therapeutics sector. Hence, companies in the human papillomavirus and cytomegalovirus therapeutics market are increasing their production capabilities of intravenous ganciclovir, especially for immunocompromised patients.

To understand how our report can bring difference to your business strategy, Ask for a brochure

On the other hand, second-line drugs such as Cidofovir and Foscarnet are also being highly preferred in the human papillomavirus and cytomegalovirus therapeutics market. These drugs help to inhibit the viral DNA polymerase over cellular polymerases. Acyclovir is another promising drug used in the treatment of cytomegalovirus and is an approved treatment in the European Union. As such, Europe is anticipated to dictate the second-highest revenue among all regions in the human papillomavirus and cytomegalovirus therapeutics market.

Longer Screening Intervals Reduce Uncertainty Associated with Vaccines

There is a growing demand for vaccines in the human papillomavirus and cytomegalovirus therapeutics market. However, researchers have found that the follow-up time has been relatively short over the years to determine the efficacy of Gardasil and Cervarix vaccines for HPV treatment. This explains why the HPV therapeutics sector is estimated to progress at a modest CAGR of ~4% during the forecast period. As such, an unrepresentative population of women older than the usual target age group of 9-13 years is also hampering growth of the human papillomavirus and cytomegalovirus therapeutics market.

Vaccines meant to treat cervical cancer usually takes decades to develop. Hence, companies in the market for human papillomavirus and cytomegalovirus therapeutics should increase their screening intervals to reduce uncertainty associated with the efficacy of vaccines. Moreover, the demand for vaccines is predicted to rise in the human papillomavirus and cytomegalovirus therapeutics market due to high survival rates of HPV patients. For instance, renowned biotech executive Michael Becker who died last year due to HPV, laid emphasis on the potential of vaccines for the treatment of HPV.

Stuck in a neck-to-neck competition with other brands? Request a custom report on Human Papillomavirus and Cytomegalovirus Therapeutics Market

Analysts’ Viewpoint

Gene-Eden-VIR/Novirin is predicted to create a ray of hope for coronavirus therapeutics, owing to its efficacy in HPV and cytomegalovirus treatment. AS1411 is found to be well tolerated in therapeutic activities for DNA Nano-based drug carriers.

Companies in the human papillomavirus and cytomegalovirus therapeutics market are becoming increasingly aware about one dose of HPV vaccine, which is relatively more effective than multiple doses. Prioritizing single-dose vaccination in less privileged countries is generating incremental opportunities for companies, since it eliminates the issue of increased spending associated with multiple doses for cancer patients. However, unrepresentative population and uncertainty in trials for HPV vaccines are inhibiting market growth. Hence, companies should aim at extending their screening intervals and target appropriate age groups to validate the efficacy of HPV vaccines.

Human Papillomavirus and Cytromegalovirus Therapeutics Market: Overview

  • The global human papillomavirus and cytromegalovirus therapeutics market comprises drugs and their applications
  • Human papillomavirus has over 100 strains responsible for various genital warts as well as cancers affecting genital and oral region of the body. Drugs for treatment of HPV include immunomodulators, keratolytics, antineoplastics, and sinecatechins.
  • Cytomegalovirus (CMV) is a double-stranded DNA virus and is a member of the Herpesviridae family, which can cause various diseases and infections. Major drug classes for these infections include antiviral drugs such as Ganciclovir, Valganciclovir, and Foscavir.
  • Therapeutic options primarily cure symptoms of the disease and are effective antiviral options. These drugs are available in the market as both branded as well as generics.
  • Rise in prevalence of HPV infections in developing and underdeveloped countries, grants from governments & international organizations for cancer treatment, and proactive government initiatives are the major factors driving the human papillomavirus and cytromegalovirus therapeutics market
  • In September 2018, the U.S. Agency for International Development (USAID) obtained Congressional approval to invest US$ 1.2 Mn in funds from fiscal year 2017 to support the integration of cervical cancer preventative services into existing voluntary family planning and reproductive health programs in Malawi and Mozambique, two low-income countries with some of the highest rates of cervical cancer in the world
  • Recurring nature of cytomegalovirus infections and diseases is a major factor fueling the growth of the global human papillomavirus and cytromegalovirus therapeutics market
  • Moreover, development of novel molecules for CMV infection and product approval by regulatory bodies boosts the growth of the global  human papillomavirus and cytromegalovirus therapeutics market

Market Segmentation: Human Papillomavirus and Cytomegalovirus Therapeutics Market

  • In terms of drug class, the global human papillomavirus and cytromegalovirus therapeutics market has been classified into immunomodulators, keratolytics, antineoplastics, and sinecatechins
  • Based on application, the global human papillomavirus and cytromegalovirus therapeutics market has been categorized into genital warts, genital cancer, oral papillomas, and others
  • In terms of distribution channel, the global human papillomavirus and cytromegalovirus therapeutics market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies
  • Based on drug class, the global human papillomavirus and cytromegalovirus therapeutics market has been split into Ganciclovir/Valganciclovir, Foscavir (Foscarnet), Cidofovir (Vistide), Letermovir (Prevymis), and others
  • In terms of application, the global human papillomavirus and cytromegalovirus therapeutics market has been segmented into retinitis, gastrointestinal ulcer, pneumonia, encephalitis, and others
  • Each of the global human papillomavirus and cytomegalovirus therapeutics market segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights
  • The global human papillomavirus and cytomegalovirus therapeutics market report provides current and future revenues (US$ Mn) for each these segments for the period from 2017 to 2027, considering 2018 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2019 to 2027, along with market size estimations.

Regional Overview: Human Papillomavirus and Cytomegalovirus Therapeutics Market

  • In terms of region, the global human papillomavirus and cytomegalovirus therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.
  • North America dominated the global human papillomavirus and cytomegalovirus therapeutics market in 2018
  • The current and future sizes of the human papillomavirus and cytomegalovirus therapeutics market in terms of revenue (US$ Mn) in these regions and their major countries have been provided in the report for the period from 2017 to 2027, with their CAGRs for the period from 2019 to 2027.
  • The study also offers a list of recommendations, highlights, and useful insights of the market, which will help new companies willing to enter the market and existing companies to increase market shares and help in the decision-making process

Major Players

  • The global human papillomavirus and cytomegalovirus therapeutics market report concludes with the company profiles section that includes key information about the major players in the market
  • Key players analyzed in the human papillomavirus and cytomegalovirus therapeutics market report are 
    • Merck & Co., Inc.
    • Bausch & Lomb Incorporated (Bausch Health Companies, Inc.)
    • AbbVie, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Mylan N.V.
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
    • Clinigen Group plc
    • Pfizer, Inc.
    • Cipla Inc.
  • Each of these players has been profiled in the global human papillomavirus and cytomegalovirus therapeutics market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments

Human Papillomavirus and Cytomegalovirus Therapeutics Market - Scope of the Report

TMR’s report on the global human papillomavirus and cytomegalovirus therapeutics market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators for the market during the forecast period from 2019 to 2027. The report provides the overall revenue of the global human papillomavirus and cytomegalovirus therapeutics market for the period from 2017 to 2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global human papillomavirus and cytomegalovirus therapeutics market for the forecast period.

The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global human papillomavirus and cytomegalovirus therapeutics market.

Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have employed a combination of top-down and bottom-up approach to study various phenomena in the global human papillomavirus and cytomegalovirus therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Furthermore, the report sheds light on changing competitive dynamics in the global human papillomavirus and cytomegalovirus therapeutics market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the global human papillomavirus and cytomegalovirus therapeutics market.

The report delves into the competitive landscape of the global human papillomavirus and cytomegalovirus therapeutics market. Key players operating in the global human papillomavirus and cytomegalovirus therapeutics market have been identified, and each one of them has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOTs are some of the attributes of players in the global human papillomavirus and cytomegalovirus therapeutics market that have been profiled in this report.

Key Questions Answered in Human Papillomavirus and Cytomegalovirus Therapeutics Market Report

  • What is the sales/revenue generated by each drug class, application, and distribution channel segment of the global human papillomavirus and cytomegalovirus therapeutics market across all regions during the forecast period?
  • What are the opportunities in the global human papillomavirus and cytomegalovirus therapeutics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which region is likely to expand at the fastest CAGR during the forecast period?
  • Which human papillomavirus and cytomegalovirus therapeutics drug class, application, and distribution channel segments are expected to generate the highest revenue globally in 2027? Which segment is projected to expand at the highest CAGR during the forecast period?
  • What is the market share or position of different companies operating in the global market in 2018?

Human Papillomavirus and Cytomegalovirus Therapeutics Market - Research Objectives and Research Approach

The comprehensive report on the global human papillomavirus and cytomegalovirus therapeutics market begins with an overview of the market, followed by the scope and objectives of this study. Following this, the report provides detailed explanation of the objectives behind this study, key industrial developments in terms of merger, acquisition, strategic partnerships, pipeline analysis, and value chain analysis have been provided.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into small sections. The entire report comprises an exhaustive collection of graphs and tables appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global human papillomavirus and cytomegalovirus therapeutics market in terms of drug class, application, distribution channel, and region. Key segments under each criteria have been studied at length, and the market share for each of them at the end of 2027 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global human papillomavirus and cytomegalovirus therapeutics market.

Human Papillomavirus and Cytomegalovirus Therapeutics Market - Segmentation

TMR’s study on the global human papillomavirus and cytomegalovirus therapeutics market includes information divided into four sections: drug class, application, distribution channel, and region. Changing industry trends and other crucial market dynamics associated with these sections of the global human papillomavirus and cytomegalovirus therapeutics market have been discussed in detail.

Drug Class

Human

Papillomavirus

  • Therapeutics
  • Immunomodulators
  • Keratolytics
  • Antineoplastics
  • Sinecatechins

Cytomegalovirus

Therapeutics

  • Ganciclovir/Valganciclovir
  • Foscavir (Foscarnet)
  • Cidofovir (Vistide)
  • Letermovir (Prevymis)
  • Others

Application

Human

Papillomavirus Therapeutics

  • Genital Warts
  • Genital Cancer
  • Oral Papillomas
  • Others

Cytomegalovirus

Therapeutics

  • Retinitis
  • Gastrointestinal Ulcer
  • Pneumonia
  • Encephalitis
  • Others

Distribution Channel

Human

Papillomavirus

Therapeutics

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Cytomegalovirus

Therapeutics

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

 

Region

North

America

Europe

Asia

Pacific

Latin

America

Middle East & Africa

\

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Human Papillomavirus Cytomegalovirus Therapeutics Market

Buy Now